Telegraph Hill Partners, a San Francisco, CA-based venture capital and growth equity firm focused on life science and healthcare sectors, held the final close of a new fund at $310m.
The fund, THP III, will back companies with advanced technologies that have already demonstrated organic revenue growth in areas including life science tools, reagents, specialty chemistries, medical technology, medical devices, healthcare IT, healthcare services, agriculture and animal health.
The fund is expected to invest in 10-12 companies across the United States.
Formed in 2001 and led by Matt Mackowski, Chairman, THP uses several investment structures such as venture capital, growth equity, buyouts and secondary acquisitions. Previous investments include Althea Technologies (acquired by Ajinomoto Co.), Ambion, (acquired by Applied Biosystems Group), Dharmacon (acquired by ThermoFisher), NEXUS Biosystems (acquired by Brooks Automation), LDR (based in Austin, TX) and Vidacare (based in San Antonio, TX).